Silvia L. F.
- Country
- Spain
- Department
- HU Virgen de las Nieves_Farmacia EECC
Research Overview
- A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization
- Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Ponsegromab in Adults with Heart Failure
- Phase IIb Multicenter Double-Blind Randomized Placebo-Controlled Trial of Intracoronary Autologous Bone Marrow-Derived Mononuclear Cells in Idiopathic Dilated Cardiomyopathy
Data & Insights
Has run more than one trial at 16 of 279 partner sites.
Specializations
Cardiovascular Medicine
The investigator specializes in advanced treatments for heart failure and cardiomyopathy, with particular emphasis on innovative therapeutic approaches for patients with compromised cardiac function.
- Heart Failure Management
- Quality of Life Assessment in Cardiac Patients
- Dilated Cardiomyopathy Treatment
Their research encompasses both conventional and emerging therapeutic strategies for cardiac conditions.
Regenerative Medicine
The investigator focuses on cell-based therapies in cardiovascular medicine, particularly exploring the potential of autologous bone marrow mononuclear cells for cardiac regeneration.
- Intracoronary Cell Therapy
- Cardiac Tissue Regeneration
- Ventricular Function Improvement
Their work extends to developing therapeutic alternatives for patients with limited treatment options.
Clinical Outcomes
The investigator evaluates health-related quality of life metrics in cardiovascular patients, focusing on comprehensive patient care approaches and therapeutic efficacy assessment.
- Patient-Reported Outcomes
- Disease-Specific Health Status
- Treatment Safety Profiles
Their research emphasizes measuring and improving patient outcomes in cardiac care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.